Disc Medicine, Inc.
IRONDrugs in Pipeline
3
Phase 3 Programs
1
Upcoming Catalysts
1
Next Catalyst
May 2027
Market Overview
Stock performance and key metrics
1 upcoming, 2 past
How IRON's past catalysts played out
Myelofibrosis; Anemia
1 drug in this indication
Polycythemia Vera (PV)
1 drug in this indication
Erythropoietic Protoporphyria
1 drug in this indication
Erythropoietic Protoporphyria (EPP)
1 drug in this indication
Polycythemia vera
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Disc Medicine, Inc.'s drug pipeline?→
CatalystAlert tracks 3 drug candidates in Disc Medicine, Inc.'s (IRON) pipeline across Phase 3, Phase 2. Its lead program is DISC-1459 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Disc Medicine, Inc.'s next FDA catalyst?→
Disc Medicine, Inc.'s (IRON) next tracked catalyst is a Phase 3 expected September 15, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track IRON biotech catalysts?→
Add IRON to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Disc Medicine, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.